BGPT: Paper Review: p73: From the p53 shadow to a major pharmacological target in anticancer therapy

Explore by Goal

Quick Explanation Copied

p73 review critique (10.1016/j.phrs.2020.105245)

The review argues that p73 isoform balance (TAp73 vs ΔNp73) and its negative regulators (e.g., MDM2/MDM4, ITCH, iASPP, mutp53) form actionable pharmacological leverage points in TP53-null/mutant cancers, while emphasizing context-dependence from isoform-specific biology.

Key strength: mechanistic breadth across structure → regulation → therapy concepts. Key weakness: most “therapeutic target” framing relies on heterogeneous preclinical models and narrative synthesis, leaving uncertain what generalizes clinically and which isoform-specific pharmacodynamics are necessary.

Long Explanation

Paper Review: p73 — From the p53 shadow to a major pharmacological target in anticancer therapy

Focus: isoform biology (TAp73 vs ΔNp73), pathway regulation, and pharmacological targeting concepts in oncology.

Core claim p73 isoform balance + negative-regulator disruption can be leveraged for anticancer therapy, especially when TP53 is null/disrupted.

Metadata extracted from provided full text

DOI: 10.1016/j.phrs.2020.105245
Type: Narrative literature review (no new primary experiments reported)
Publication venue: Pharmacological Research (per provided identifiers)
Publication timing: Received 11 Aug 2020; accepted 2 Oct 2020 (manuscript metadata)

Visualization-first: p73 as a two-isoform pharmacological system

Mechanistic network (from the review’s described interactions)

Legend: directed arrows encode activation/stabilization vs antagonism as described in the review.

What the review does well

1) Isoform architecture + domain logic is explicitly connected to therapy

The review emphasizes p73’s modular structure and isoform generation (promoter usage and C-terminal splicing), supporting mechanistic rationale for why isoform-specific modulation matters clinically.

2) Regulatory-network breadth (transcriptional + post-translational) is pharmacologically framed

Examples include transcriptional control of TAp73 via E2F1/C-EBPα/ZEB and post-translational control via ITCH/YAP1/MDM2, which the review then maps to “strategies” such as displacement of inhibitory complexes.

3) Therapy concepts are diverse (small molecules, peptides, RNA approaches) rather than a single pathway narrative

The review lists multiple pharmacological approaches aimed at (i) upregulating TAp73, (ii) inhibiting ΔNp73, or (iii) disrupting negative regulator interactions (e.g., MDM2-mutp53, iASPP complexes) and discusses preclinical evidence and translational obstacles.

Skeptical critique: where the review’s reasoning is strong vs uncertain

Known/established (high confidence from cited literature)

Isoform antagonism is a central organizing principle: ΔNp73 is described as oncogenic and dominant-negative by inhibiting TAp73 and p53 functions, while TAp73 is described as pro-apoptotic/genome-stability supporting in stress contexts.
p73 is regulated by stability/ubiquitin and cofactor mechanisms (e.g., ITCH-mediated degradation; YAP1 competition; MDM2 suppression).

Uncertain / context-dependent (review framing risk)

Clinical translation depends on isoform-selective pharmacodynamics. Even if a compound increases “p73,” it may simultaneously alter ΔNp73 and thereby negate net tumor-suppressive output; the review explicitly highlights the challenge of antagonistic isoforms, but the summarized therapeutic approaches often come from heterogeneous experimental contexts.
Narrative review = citation selection risk. Without systematic inclusion criteria, conclusions may overweight positive modulators and underrepresent contradictory findings, a common limitation for narrative syntheses.
Species/model mismatch remains a practical bottleneck. The review uses mouse knockout models and xenografts to motivate causal roles, but these systems may not capture human tumor microenvironments, immune contexts, or the exact isoform expression dynamics.

Visualization: therapy mechanisms as “attack surfaces”

Attack surfaces described in the review (qualitative counts from Table 1 excerpt)

Note: the provided Table 1 excerpt in the full text is incomplete (only some rows are visible). The chart below therefore visualizes only what is present in the excerpt, not the full paper’s entire table content.

Table 1 excerpt visible here includes nutlin-3a (MDM2 displacement) and RETRA (mutp53–p73 displacement), while other strategies are only partially displayed.

Critically selected mechanistic anchors (examples from cited literature)

MDM2-family → p73 functional inhibition

MDM2 is described as an inhibitor of p73 function (review cites MDM2/p73 inactivation mechanisms).

Cofactor-mediated specificity: ASPP1/2 vs iASPP

The review states ASPP1/2 potentiate TAp73 DNA-binding activity on pro-apoptotic gene promoters (e.g., PUMA, BAX, PIG3), whereas iASPP acts as a negative regulator of TAp73.
Coactivation of p53-family by ASPP proteins is supported by mechanistic literature, which the review leverages for p73 therapeutic logic.

Stability axis: ITCH vs YAP1

ITCH promotes p73 turnover; YAP1 stabilizes p73 by preventing ITCH-mediated ubiquitination—an example of how protein-protein interaction networks translate into pharmacological targeting strategies.

What would most disprove the review’s therapeutic premise?

Isoform-agnostic “p73 increase” would not be sufficient: if interventions that elevate total p73 fail to shift the TA/ΔN ratio toward TAp73-dominant transcriptional outputs (and/or do not reduce ΔNp73 functional inhibition), then the premise that p73 is a major target would weaken. The review itself states that disrupting the TA/ΔN ratio impacts progression and therapy effectiveness.
Specificity tests in p73-dependent contexts: if key pharmacological outcomes attributed to p73 remain unchanged in p73 loss-of-function models (isoform-specific), then the causal mapping from p73 modulation to anti-tumor phenotypes would be undermined. This is a general experimental falsification principle; the review discusses isoform-specific knockout models and antagonistic isoform functions, which makes such dependency tests particularly meaningful.

BGPT interactive “go deeper” links

Author reviews (from provided author list)

Feedback:

Updated: April 03, 2026